[go: up one dir, main page]

Chisari et al., 2021 - Google Patents

Glucose and amino acid metabolic dependencies linked to stemness and metastasis in different aggressive cancer types

Chisari et al., 2021

View HTML
Document ID
8394799830726091834
Author
Chisari A
Golán I
Campisano S
Gélabert C
Moustakas A
Sancho P
Caja L
Publication year
Publication venue
Frontiers in Pharmacology

External Links

Snippet

Malignant cells are commonly characterised by being capable of invading tissue, growing self-sufficiently and uncontrollably, being insensitive to apoptosis induction and controlling their environment, for example inducing angiogenesis. Amongst them, a subpopulation of …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Chisari et al. Glucose and amino acid metabolic dependencies linked to stemness and metastasis in different aggressive cancer types
Wang et al. Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies
Xu et al. Reprogramming of amino acid metabolism in pancreatic cancer: recent advances and therapeutic strategies
Yoo et al. Glutamine reliance in cell metabolism
Lemberg et al. Clinical development of metabolic inhibitors for oncology
Wei et al. Metabolism of amino acids in cancer
Tang et al. New insights into molecules and pathways of cancer metabolism and therapeutic implications
Diao et al. Ferroptotic therapy in cancer: benefits, side effects, and risks
Mates et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer
Zhang et al. KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
van der Mijn et al. Novel drugs that target the metabolic reprogramming in renal cell cancer
Kim et al. ROS homeostasis and metabolism: a critical liaison for cancer therapy
Elf et al. Targeting glucose metabolism in patients with cancer
Cairns et al. Regulation of cancer cell metabolism
Yuan et al. Metabolism of asparagine in the physiological state and cancer
Jahani et al. Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy
Le et al. Targeting ferroptosis in gastric cancer: Strategies and opportunities
Yang et al. Arginine metabolism: a potential target in pancreatic cancer therapy
Hope et al. The role of non-essential amino acids in T cell function and anti-tumour immunity
Zhu et al. How DNA methylation affects the Warburg effect
Cho et al. Matrine suppresses KRAS‐driven pancreatic cancer growth by inhibiting autophagy‐mediated energy metabolism
Wang et al. Amino acid metabolic reprogramming in tumor metastatic colonization
Shi et al. RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Coffey et al. Metabolic alterations in hereditary and sporadic renal cell carcinoma
Zhou et al. The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment